Skip to main content

Galapagos Teams with Flanders Univ. Institute for Biotech to ID Alzheimer s Genes

NEW YORK, Aug. 30 – Galapagos Genomics and the Flanders Interuniversity Institute for Biotechnology have entered a collaboration to identify and validate Alzheimer-related gene targets, the companies announced Thursday.

Under the terms of the collaboration, Galapagos, a privately held company based in Belgium, integrate its PhenoSelect gene function discovery platform with the Flanders Interuniversity Institute for Biotechnology’s (VIB) cell-based presesilin-gamma-secretase assays to screen its human gene library for genes involved in Alzheimer’s Disease.

Financial details of the deal were not disclosed.

After identifying target genes, Galapagos plans to work with VIB to validate potential drug targets.

“This collaboration is an important step forward for us as a target discovery focused company,” Galapagos’s CEO Onno van de Stolpe said in a statement.

Earlier this month, Galapagos announced a collaboration with Vertex Pharmaceuticals to identify the function of various proteins.  In June, the company entered a partnership with Bayer Yakuhin of Japan to identify and evaluate the function of proteins associated with asthma.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.